Michael Calub
Acute Care · Pasadena, CANPI 1831933845
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 75 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$456
- AstraZeneca$183
- Gilead$180
- Incyte Corporation$116
- Array Biopharma Inc$103
- Seagen Inc.$99
- plus $1K from 23 others
What the payments were for
- Food & beverage$1,96591%
- Education$1959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $456 |
| AstraZeneca(2 entities) | 8 | $183 |
| Gilead | 4 | $180 |
| Incyte Corporation | 4 | $116 |
| Array Biopharma Inc | 4 | $103 |
| Seagen Inc. | 1 | $99 |
| Pfizer | 3 | $92 |
| Eisai Inc. | 4 | $87 |
| Tersera Therapeutics LLC | 2 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| Novartis | 3 | $65 |
| AbbVie | 2 | $62 |
| Exelixis Inc. | 2 | $56 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Bayer | 2 | $52 |
| Boehringer Ingelheim | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Deciphera Pharmaceuticals Inc. | 1 | $33 |
| Taiho Oncology, Inc. | 1 | $31 |
| Bristol Myers Squibb | 1 | $29 |
| Octapharma USA, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Sanofi | 1 | $25 |
| Geron Corporation | 1 | $24 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $21 |
| GSK | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
How this compares
$2,160 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.
Other acute care in Pasadena
- Kasalyn ThuvamontolratPasadena$20K
- Shumin ZhenPasadena$8K
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.